Finance

Lists
Why is VALN up 3.54%?
Dive Deeper
VALN:NASDAQ
Valneva SE
$5.70
+3.54%
(+0.19) 1D
Oct 20, 2:55:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VALN...
Open
$5.54
High
$5.84
Low
$5.54
Mkt. cap
534.85M
Avg. vol.
23.62K
Volume
10.96K
52-wk high
$12.18
52-wk low
$4.75
EPS
-$1.99
Beta
1.52
Shares outstanding
94.89M
No. of employees
620
Open
$5.54
High
$5.84
Low
$5.54
Mkt. cap
534.85M
Avg. vol.
23.62K
Volume
10.96K
52-wk high
$12.18
52-wk low
$4.75
EPS
-$1.99
Beta
1.52
Shares outstanding
94.89M
No. of employees
620
News stories
From web sources and news partners
Profile
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
About Valneva SE
CEOThomas Lingelbach
Employees620
Founded2013
Headquarters-
SectorBiotechnology
Websitevalneva.com
Analyst ratings
Based on 3 analysts giving stock ratings to VALN in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for VALN in the last 3 months.
Highest
Current $5.70
$18.00 (+215.51%)
Average
$13.67 (+139.61%)
Lowest
$11.00 (+92.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$18.00
+215.5%
09/21/2026
Vamil Divan
Guggenheim
Buy
Maintained
$11.00
+92.8%
08/13/2026
Tara Bancroft
TD Cowen
Buy
Initiated
$12.00
+110.3%
08/11/2026
Rajan Sharma
Goldman Sachs
Sell
Downgraded
$4.90
-14.1%
04/22/2026
Maury Raycroft
Jefferies
Buy
Maintained
$15.00
+162.9%
03/23/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
-€0.40 / -€0.08
-395.44%miss
Revenue / Est. (EUR)
34.94M / 37.72M
-7.39%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
29.41M
47.69M
30.90M
34.94M
Cost of goods sold
51.19M
61.64M
41.40M
48.36M
Cost of revenue
51.19M
61.64M
41.40M
48.36M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.80M
16.54M
15.14M
13.77M
Operating expense
15.56M
13.73M
13.20M
12.75M
Total operating expenses
66.76M
75.37M
54.60M
61.11M
Operating income
-37.35M
-27.68M
-23.70M
-26.17M
Other non operating income
-37.00K
-
-
874.00K
EBT including unusual items
-43.47M
-51.08M
-31.25M
-31.77M
EBT excluding unusual items
-43.70M
-51.49M
-31.25M
-31.75M
Income tax expense
882.00K
-1.06M
824.00K
-566.00K
Effective tax rate
-2.03%
2.08%
-2.64%
1.78%
Other operating expenses
-3.24M
-2.81M
-1.93M
-1.02M
Net income
-44.36M
-50.02M
-32.07M
-31.20M
Net profit margin
-150.82%
-104.89%
-103.78%
-89.31%
Earnings per share
-
-
-0.18
-0.17
Interest and investment income
845.00K
-
526.00K
-
Interest expense
-5.67M
-24.71M
-5.09M
-5.54M
Net interest expenses
-4.83M
-24.71M
-4.57M
-5.54M
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.96M
-26.96M
-19.46M
-21.14M
Gain or loss from assets sale
-230.00K
432.00K
-
14.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps